TOELY has performed on-par with the rest of the sector throughout the Covid era, despite its OTC status and comparative obscurity for ordinary traders (70B mkt cap vs ASML, AMAT etc). Another new ATH reached just before earnings, and a rosy outlook ahead. Rising support levels still accelerating, price action above all meaningful MAs. On track for more gains towards the 135-145 target.
Komentarz:
Retested the "new support" on 04-05 May, and it has unsurprisingly held.